Form 4: Mineralys Therapeutics Director Transfers Equity

Mineralys Therapeutics Director and 10% owner Brian Taylor Slingsby reported the grant and subsequent transfer of Restricted Stock Units and stock options to Catalys Pacific Fund, LP.

Summary

• Brian Taylor Slingsby, a Director and 10% owner of Mineralys Therapeutics, Inc. (MLYS), reported transactions on February 19, 2026, involving common stock and stock options.
• He was granted 6,200 Restricted Stock Units (RSUs) for no cash consideration, each representing a contingent right to receive one share of common stock upon vesting in one annual installment following the grant date.
• Concurrently, these 6,200 RSUs were transferred from Slingsby's direct ownership to Catalys Pacific Fund, LP, where he retains indirect beneficial ownership.
• He was also granted 8,300 stock options with an exercise price of $28.06, which will vest in 12 substantially equal monthly installments following the grant date.
• These 8,300 stock options were similarly transferred from Slingsby's direct ownership to Catalys Pacific Fund, LP, where he retains indirect beneficial ownership.
• Following these transactions, Slingsby's direct beneficial ownership of common stock and stock options is zero, while his indirect beneficial ownership through Catalys Pacific Fund, LP is 7,910,038 shares of common stock and 8,300 stock options.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transfer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard equity compensation and internal transfers for a director and significant owner, which aligns interests without indicating new strategic direction or financial performance.

Positives

• The grant of 6,200 Restricted Stock Units and 8,300 stock options to Brian Taylor Slingsby aligns his interests with long-term shareholder value.
• The vesting schedule for RSUs (one annual installment) and stock options (12 monthly installments) encourages continued engagement and performance from a key director and significant owner.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to directors and significant owners like Brian Taylor Slingsby are standard practice in the biotechnology and pharmaceutical industry, aiming to align executive incentives with company performance and shareholder interests. The transfer to an affiliated fund (Catalys Pacific Fund, LP) is common for venture capital or private equity partners who hold board seats, reflecting their investment structure.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director and 10% owner, with vesting schedules, is consistent with compensation practices seen in comparable early-stage biotech companies.
• Similar equity incentive structures are often employed by companies like Relay Therapeutics or Denali Therapeutics for their board members and significant investors to ensure long-term commitment and align interests with company growth.

Related Party Transactions

• Transfer of 6,200 Restricted Stock Units and 8,300 stock options from Brian Taylor Slingsby to Catalys Pacific Fund, LP.
• Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP, which in turn is the general partner of Catalys Pacific Fund, LP. This establishes a clear related-party relationship for the transfers and indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a significant owner and director with long-term shareholder value. The indirect ownership structure through Catalys Pacific Fund, LP is transparently disclosed.

Next Steps

• The 6,200 Restricted Stock Units will vest in one annual installment following the grant date of February 19, 2026.
• The 8,300 stock options will vest in 12 substantially equal monthly installments following the grant date of February 19, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity grants and internal transfers for a director and significant owner, Brian Taylor Slingsby, within his affiliated investment fund. Such transactions are typically pre-arranged and do not signal new fundamental information about the company's operational performance or strategic direction. While the grants align insider interests, they do not provide a basis for a strong buy or sell recommendation, thus a 'hold' is appropriate as it maintains current positions based on existing company fundamentals.

Keywords

Mineralys Therapeutics, MLYS, Brian Taylor Slingsby, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSU, Equity Grant, Director, 10% Owner, Catalys Pacific Fund, Beneficial Ownership